Historique de carrière de Ross G. Clark
Anciens postes connus de Ross G. Clark
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Directeur/Membre du Conseil | 01/12/2001 | 21/06/2008 |
| Directeur Technique/Scientifique/R&D | 01/12/2001 | 21/06/2008 | |
| Auckland University | Corporate Officer/Principal | 01/09/1997 | 21/06/2008 |
| NeuronZ Ltd. | Directeur Technique/Scientifique/R&D | 01/10/1997 | 01/01/2000 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Directeur Technique/Scientifique/R&D | 01/01/1990 | 01/01/1997 |
| ViaLactia Biosciences (NZ) Ltd. | Directeur/Membre du Conseil | 01/07/1999 | - |
| Tercica Ltd. | Corporate Officer/Principal | 01/09/2000 | - |
Formation de Ross G. Clark
| Massey University | Doctorate Degree |
Statistiques
Internationale
| Nouvelle-Zélande | 6 |
| Etats-Unis | 3 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 3 |
| Director/Board Member | 2 |
| Corporate Officer/Principal | 2 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
| Tercica Ltd. | |
| NeuronZ Ltd. | |
| ViaLactia Biosciences (NZ) Ltd. | |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
- Bourse
- Insiders
- Ross G. Clark
- Expérience
